AstraZeneca Pharma rises on getting permission for sale, distribution of Datopotamab Deruxtecan powder [Healthcare]
AI Summary1 min read
TL;DR
AstraZeneca Pharma India has received approval to sell and distribute Datopotamab Deruxtecan powder, a medicine in its oncology portfolio, as part of its focus on healthcare innovations.
Tags
Pharmaceuticals & DrugsHealthcare
The Company is engaged in the business of manufacture, distribution and marketing of life-changing medicines in crucial areas of healthcare including oncology, cardiovascular, diabetes, renal, metabolic and respiratory. The company has an innovative portfolio in crucial areas of healthcare including cardiovascular, renal & metabolic diseases, oncology and respiratory. AstraZeneca Pharma India is a subsidiary of AstraZeneca Pharmaceuticals AB, Sweden, which is an indirect subsidiary of AstraZeneca PLC.